Since there are no SMARCB1 wildtype pediatric kidney cancer cell lines in CCLE, we compared the sensitivity to bortezomib or MLN2238 in our RMC models with wildtype SMARCB1 patient-derived Wilms tumor cell line, CLF_PEDS1012_T (Figure 4b–c and Figure 3—figure supplement 1j). The gene discussed is SMARCB1; the disease is Nephroblastoma.